Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab
International Journal of Molecular Sciences · 24.03.2026 · 27 (7) · 2947
DOI: 10.3390/ijms27072947 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.03.2026. Verfasst von Viola Bianca Serio und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genomics & Systems Biology Lab, University of Siena, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGenerationEU of Piano Nazionale di Ripresa e Resilienza (PNRR), "Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale (PRIN)" - PRIN 2022 PNRR.
Abstract (Originalsprache)
Programmed death-ligand 1 (PD-L1) expression is routinely used to guide immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (NSCLC), yet clinical benefit remains heterogeneous even among PD-L1–high tumors. Liquid biopsy based on cell-free DNA (cfDNA) enables minimally invasive, real-time monitoring of tumor evolution. We report four cases of metastatic lung adenocarcinoma treated with atezolizumab, integrating longitudinal whole-exome sequencing (WES) of cfDNA with radiological assessment. Four patients with PD-L1–positive (≥60%) metastatic NSCLC received atezolizumab monotherapy. Serial cfDNA samples (1–3 per patient) were analyzed by high-depth WES. Distinct molecular trajectories paralleled divergent clinical outcomes. One patient achieved a complete molecular response, characterized by progressive clearance of KRAS, ATM, and NF1 mutant clones, which was concordant with radiological remission. A second patient showed an initial molecular response, followed by clonal rebound of TP53, NF1, and NOTCH2 mutant populations and the emergence of PTEN and KIF1A variants, suggesting clinical progression. Two patients exhibited primary resistance despite high PD-L1 expression, with persistent or expanding clones and early subclonal diversification; in one case, new EGFR and BRAF alterations emerged under treatment pressure. Notably, switching to platinum-based chemotherapy in a non-responder induced a measurable molecular response, highlighting discordance between PD-L1 status and immunotherapy efficacy. Longitudinal cfDNA WES captured dynamic clonal remodeling under immunotherapy and anticipated radiological outcomes. These findings underscore the clinical necessity of integrating dynamic molecular monitoring by liquid biopsy to overcome the limitations of static PD-L1 assessment, refine therapeutic stratification, and identify early resistance mechanisms in advanced NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Genomics & Systems Biology Lab, University of Siena, 53100 Siena, Italy.
- Med Biotech Hub and Competence Centre, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
- Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
- Oncology Unit, Azienda Ospedaliero Universitaria Senese, 53100 Siena, Italy.
- Thoracic Surgery Unit, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy.
- Bioengineering Laboratory, University of Siena, 53100 Siena, Italy.
ORCID-Profile: Viola Bianca Serio, Debora Maffeo, Alberto Balistreri, Gianluca Santamaria, Niccolò Vono, Francesca Mari, Francesca Colombo, Elisa Frullanti, Maria Palmieri
Förderung
- NextGenerationEU of Piano Nazionale di Ripresa e Resilienza (PNRR)
- "Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale (PRIN)" - PRIN 2022 PNRR
Zitieren
APA
Serio, V. B., Regoli, T., Maffeo, D., Martellucci, I., Rosati, D., Ghisalberti, M., Balistreri, A., Santamaria, G., Vono, N., Mari, F., Colombo, F., Frullanti, E., & Palmieri, M. (2026). Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab. International Journal of Molecular Sciences, 27(7), 2947. https://doi.org/10.3390/ijms27072947
Vancouver
Serio VB, Regoli T, Maffeo D, Martellucci I, Rosati D, Ghisalberti M, et al. Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab. International Journal of Molecular Sciences. 2026;27(7):2947. doi:10.3390/ijms27072947
BibTeX
@article{Serio2026,
author = {Serio, Viola Bianca and Regoli, Tommaso and Maffeo, Debora and Martellucci, Ignazio and Rosati, Diletta and Ghisalberti, Marco and Balistreri, Alberto and Santamaria, Gianluca and Vono, Niccolò and Mari, Francesca and Colombo, Francesca and Frullanti, Elisa and Palmieri, Maria},
title = {Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {7},
pages = {2947},
doi = {10.3390/ijms27072947}
}
EUVIMED